Tin Mesoporphyrin IX (chloride): Potent Heme Oxygenase Inhibitor for Metabolic and Pathogenesis Research

Executive Summary: Tin Mesoporphyrin IX (chloride) is a crystalline compound with a molecular weight of 754.3, used as a potent and competitive inhibitor of heme oxygenase (HO) at nanomolar affinity (Ki = 14 nM), demonstrating robust in vitro and in vivo efficacy (APExBIO). It reduces serum bilirubin in neonatal hyperbilirubinemia models and inhibits hepatic, renal, and splenic HO activity for extended periods (animal studies). The compound enables metabolic disease and insulin resistance research by modulating HO-mediated heme catabolism. No clinical trials have been reported to date, and its use is restricted to research applications. All claims are grounded in peer-reviewed literature and product documentation (Koyaweda et al., 2026).

Biological Rationale

Heme oxygenase (HO) catalyzes the degradation of heme to biliverdin, ferrous iron, and carbon monoxide. This pathway regulates intracellular heme levels and is central to redox and metabolic homeostasis (Koyaweda et al., 2026). HO-1 induction modulates reactive oxygen species (ROS) and impacts cellular signaling, influencing pathogenesis in viral infections and metabolic disease models. Inhibition of HO activity provides a means to dissect its mechanistic role in heme catabolism, redox modulation, and signaling. Research compounds such as Tin Mesoporphyrin IX (chloride) allow scientists to probe the functional consequences of HO inhibition in animal and cell models (APExBIO).

Mechanism of Action of Tin Mesoporphyrin IX (chloride)

Tin Mesoporphyrin IX (chloride) is a synthetic porphyrin analog. It competitively binds to the active site of heme oxygenase, displacing native heme substrate. The inhibition constant (Ki) is 14 nM, reflecting high affinity and specificity (APExBIO). This compound blocks the enzymatic conversion of heme to biliverdin, reducing downstream production of bilirubin and carbon monoxide. In animal models, administration at 1 pmol/kg body weight inhibits hepatic, renal, and splenic HO activity for extended durations. The inhibition is both potent and sustained, making it superior to less stable or less selective inhibitors in assay settings (related review).

Evidence & Benchmarks

• Tin Mesoporphyrin IX (chloride) inhibits HO activity in vitro with a Ki of 14 nM, demonstrating high-affinity competitive inhibition (APExBIO).
• In vivo administration at 1 pmol/kg in animal models results in significant inhibition of HO activity in the liver, kidney, and spleen for extended periods (APExBIO).
• Treatment leads to reduced serum bilirubin levels in neonatal hyperbilirubinemia models, confirming functional inhibition of HO-mediated heme catabolism (Koyaweda et al., 2026).
• HO-1 modulation, including its inhibition, alters intracellular ROS and affects viral morphogenesis in HBV models (Koyaweda et al., 2026).
• APExBIO’s C5606 compound is stable at -20°C and maintains solubility up to 0.5 mg/ml in DMSO and 1 mg/ml in DMF for short-term use (APExBIO).

This article extends the mechanistic focus found in 'Tin Mesoporphyrin IX (chloride): Advancing Heme Oxygenase...' by providing detailed evidence and updated benchmarks for in vivo efficacy and workflow integration. For troubleshooting and scenario-driven guidance, see 'Tin Mesoporphyrin IX (chloride): Reliable Heme Oxygenase ...', which this article updates with stricter quantitative conditions and new references.

Applications, Limits & Misconceptions

Tin Mesoporphyrin IX (chloride) is used in:

• Heme oxygenase activity assays for biochemical and pharmacological research.
• Metabolic disease research, including models of insulin resistance and metaflammation.
• Studies of HO signaling in redox biology and viral pathogenesis, such as HBV research (Koyaweda et al., 2026).
• Dissecting the role of HO in heme catabolism and its downstream metabolic products.

Limits:

• No clinical trial data; restricted to preclinical and in vitro research.
• Not suitable for therapeutic use in humans.
• Assay interference possible if used at concentrations exceeding solubility limits or in incompatible solvents.

Common Pitfalls or Misconceptions

• Assuming Tin Mesoporphyrin IX (chloride) is clinically approved: It is not approved for medical use and is for research only (APExBIO).
• Overestimating selectivity: While highly selective for HO, off-target effects are possible at supraphysiological concentrations or in non-mammalian systems.
• Misusing solvents: Exceeding 0.5 mg/ml in DMSO or 1 mg/ml in DMF may result in precipitation and loss of activity.
• Ignoring storage: Solutions should not be stored long-term; -20°C storage is recommended for the solid form only.
• Confusing heme oxygenase isoforms: Most data pertain to HO-1; effects on HO-2 are less characterized.

Workflow Integration & Parameters

For optimal results in heme oxygenase activity assays, Tin Mesoporphyrin IX (chloride) should be dissolved at up to 0.5 mg/ml in DMSO or 1 mg/ml in DMF. Solutions are intended for short-term use (< 1 week). The compound is stable as a crystalline solid at -20°C. Researchers should titrate inhibitor concentrations based on enzyme source and assay sensitivity. In animal studies, a single dose of 1 pmol/kg body weight is effective for hepatic, renal, and splenic HO inhibition. Monitor for precipitation and always verify compound integrity before use (see advanced workflow guidance).

Conclusion & Outlook

Tin Mesoporphyrin IX (chloride) is a validated, high-affinity tool compound for dissecting the heme oxygenase signaling pathway in metabolic, redox, and pathogenesis research. Its stability, specificity, and robust inhibition profile position it as a gold standard for biochemical investigation. APExBIO’s C5606 formulation is widely adopted for in vitro and in vivo studies, though clinical translation remains unexplored. Continued research may reveal additional roles for HO modulation in disease models and viral pathogenesis, highlighting the need for precise, reliable inhibitors like Tin Mesoporphyrin IX (chloride).